Sequent Scientific Share News - Latest Updates, Live News & More

Latest news about Sequent Scientific

Sequent Scientific Limited Officially Renamed to Viyash Scientific Limited with Effect from January 8, 2026 1 day ago

Sequent Scientific Limited has officially changed its name to Viyash Scientific Limited with effect from January 8, 2026, following ROC approval and fresh Certificate of Incorporation. The transformation was approved by shareholders via postal ballot on December 28, 2025, after the initial proposal was made to stock exchanges on November 27, 2025. The company maintains its CIN L99999TS1985PLC196357 and must display both old and new names for two years as per regulatory requirements.

Sequent Scientific Allots 1 Lakh Equity Shares Under ESOP 2020 Scheme Dec 30, 2025

Sequent Scientific VP Ashish Kakabalia Resigns From Senior Management Dec 23, 2025

CA Hull Investments Acquires 31.20% Stake in Sequent Scientific via Amalgamation Dec 16, 2025

Sequent Scientific Announces Record Dates and Share Exchange Ratios for Merger Processes Nov 22, 2025

More news about Sequent Scientific

21Nov 25

SeQuent Scientific Reports Strong Q2 Results and Secures NCLT Approval for Merger

SeQuent Scientific, India's largest pure-play animal health company, reported robust Q2 financial results with 15% YoY revenue growth to INR 4,240.00 million and EBITDA of INR 657.00 million. The formulations segment grew 18% YoY, while API segment grew 7%. The NCLT approved a merger between SeQuent and Viyash Group, expected to create R&D and manufacturing synergies. Strategic initiatives include expansion into Mexico, product launches in Brazil, and successful FDA audit completion. The company aims to sustain 20%+ EBITDA margins and focuses on expanding its product pipeline, especially in companion animal health.

17Nov 25

Sequent Scientific Reports Robust Q2 Performance with 465% Surge in Net Profit

Sequent Scientific Ltd has reported impressive Q2 FY2026 results. Revenue increased by 13.51% to ₹420.00 crore. Net profit surged by 465.38% to ₹14.70 crore. EBITDA grew by 42.46% to ₹55.70 crore. EBITDA margin expanded to 13.26% from 10.57%. The company's performance indicates strong market position and operational excellence.

15Nov 25

Sequent Scientific Reports Revenue Growth but Lower Profits in Q2 FY26

Sequent Scientific Limited announced Q2 FY26 results with consolidated revenue of ₹4,261.40 million, up 14.2% year-over-year. However, profit after tax declined 21.9% to ₹196.00 million. The company saw increased material costs and employee benefits expenses. Basic EPS improved to ₹0.59 from ₹0.11 in Q2 FY25. The board approved unaudited financial results for the quarter and half-year ended September 30, 2025, and awaits NCLT approval for a composite scheme of amalgamation involving subsidiaries.

12Nov 25

Sequent Scientific Allots 11.63 Lakh Shares Under ESOP 2020, Boosts Capital

Sequent Scientific's Nomination and Remuneration Committee approved the allotment of 11,63,301 equity shares under ESOP 2020 at ₹86 per share, increasing the company's paid-up capital from ₹50.59 crores to ₹50.82 crores. This strategic move continues the company's focus on employee engagement and ownership in the pharmaceuticals sector.

08Nov 25

Sequent Scientific Shareholders Approve Name Change to Viyash Scientific Limited

Sequent Scientific Limited has successfully completed its postal ballot process with shareholders overwhelmingly approving the name change to 'Viyash Scientific Limited' and related corporate actions. The voting concluded on December 28, 2025, with 99.99% approval rate for both the name change resolution and the alteration of Objects Clause, demonstrating strong shareholder support for the company's strategic transformation.

03Oct 25

SeQuent Scientific Seeks Shareholder Approval for Anuj Poddar's Appointment as Non-Executive Director

Sequent Scientific has initiated a postal ballot to seek shareholder approval for appointing Anuj Poddar as a Non-Executive Director. Poddar, currently Managing Director and Asia Co-Head of Global Portfolio Solutions at Carlyle, was initially appointed as an Additional Non-Executive Director on September 5, 2025. If approved, he will serve as a nominee of The Carlyle Group. The e-voting period runs from October 4 to November 2, 2025, with results expected by November 4. Poddar brings extensive experience from roles at Carlyle, Bajaj Electricals, and Viacom18 Media. He will not receive sitting fees or commission but will be reimbursed for company-related expenses.

04Sept 25

Sequent Scientific-Viyash Life Sciences Merger Secures 99.98% Shareholder Approval

Sequent Scientific's public shareholders overwhelmingly approved the merger with Viyash Life Sciences, with 99.98% voting in favor. The ₹8,000 crore deal combines Carlyle's portfolio companies in animal and human health. Hari Babu Bodepudi, Viyash's founder, will become the group CEO-designate and second-largest shareholder. The merged entity will operate 15-16 manufacturing sites, enhancing backward integration and cross-sector opportunities in both animal and human health markets.

13Aug 25

Sequent Scientific Reports Strong Q1 FY26 Results with 13.1% Revenue Growth and 25% EBITDA Jump

Sequent Scientific, an animal health company, reported robust Q1 FY2026 results. Revenue increased 13.1% to INR 4,414.00 million, Pre-ESOP EBITDA grew 25% to INR 602.00 million, and profit after tax surged 93.7%. The formulations business grew 13% year-on-year, with strong performance in Europe and emerging markets. The API segment reached INR 100.00 crore, growing 14% year-on-year. Strategic developments include GMP approval for the Spanish facility, expansion in Mexico, and progress on the merger with Viyash Life Sciences. The combined entity shows promising growth with revenue up 8.7% and EBITDA up 21% year-on-year.

08Aug 25

Sequent Scientific Announces Leadership Changes and Reports Strong Q1 FY26 Performance

Sequent Scientific Limited has announced leadership changes contingent on its merger with Viyash Lifesciences. Dr. Hari Babu Bodepudi is set to become Managing Director and Group CEO post-merger, while current MD Rajaram Narayanan will transition to CEO - Animal Health. The company reported robust Q1 FY26 results with revenue at ₹4,414.20 million (13.1% YoY growth) and PAT at ₹175.70 million (94% YoY increase). The merger process is progressing with necessary approvals and is expected to complete within 12-15 months from September 2024.

08Aug 25

SeQuent Scientific Reports Strong Q1 Results with 13% Revenue Growth and 94% PAT Surge

Sequent Scientific, an animal health sector company, reported robust Q1 financial results. Consolidated revenue increased 13.1% year-on-year to ₹4,414.00 million, while adjusted EBITDA rose 24.7% to ₹602.00 million. Net profit surged 93.7% to ₹176.00 million, with EBITDA margins improving by 120 basis points to 13.6%. The formulations business showed growth across Europe and emerging markets, while the API segment grew 14%. The company's merger with Viyash Life Sciences is progressing, with regulatory requirements expected to be completed in the coming months.

28Jul 25

Sequent Scientific Sets Stage for Major Amalgamation with Shareholder and Creditor Meetings

Sequent Scientific Limited (SSL) has scheduled meetings on August 30, 2025, for equity shareholders and unsecured trade creditors to approve a Composite Scheme of Amalgamation involving SSL and nine other companies. The meetings will be held via video conferencing, with e-voting available from August 26 to 29, 2025. The amalgamation includes companies such as Symed Labs Limited, Vandana Life Sciences Private Limited, and Sequent Research Limited. This move complies with NCLT orders and SEBI regulations, potentially reshaping SSL's corporate structure in the life sciences industry.

29May 25

Sequent Scientific's Merger with Viyash Advances: Stock Exchange Approvals Secured

Sequent Scientific has obtained approvals from stock exchanges for its proposed merger with Viyash, marking a significant step in the consolidation process. The company has subsequently filed for clearance with the National Company Law Tribunal (NCLT), a crucial step for legal consolidation. This merger is expected to enhance operational synergies, expand market presence, and strengthen the combined entity's position in the pharmaceutical sector. The focus now shifts to obtaining NCLT clearance as the merger proceedings continue.

20May 25

SeQuent Scientific Reports ₹44.3 Crore Net Profit in Recent Financial Year

SeQuent Scientific, a leading animal health company, has reported a significant financial turnaround. The company posted a net profit of ₹44.3 crore for the recent financial year, recovering from a ₹54.6 crore loss in the previous year. Revenue grew by 13.3% to ₹1551.40 crore. In the most recent quarter, net profit was ₹16.3 crore, with revenue increasing 11.11% year-over-year to ₹400.00 crore. EBITDA rose 43.0% to ₹46.20 crore, with the EBITDA margin expanding to 11.51%. Despite strong performance, no dividend was declared.